EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Iron chelation therapy for children with transfusion‐dependent β‐thalassemia: How young is too young?

Gian Luca Forni iD, Antonis Kattamis, Kevin H M Kuo iD, Aurelio Maggio, Sujit Sheth, Ali T Taher iD, Vip Viprakasit iD

Pediatric Blood & Cancer · 2024-08 · 71 (8)

DOI: 10.1002/pbc.31035 ↗

At a glance

Übersichtsarbeit in Pediatric Blood & Cancer, published online on 2024-05-16. Written by Gian Luca Forni and 6 co-authors. Institution: ForAnemia Foundation, Genoa, Italy. Major MEDLINE topics: beta-Thalassemia, Iron Chelating Agents, Iron Overload, Chelation Therapy. Cited 9 times so far (Crossref); 48 references. Funded by: Pharmacosmos.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

In this review, we provide a summary of evidence on iron overload in young children with transfusion‐dependent β‐thalassemia (TDT) and explore the ideal timing for intervention. Key data from clinical trials and observational studies of the three available iron chelators deferoxamine, deferiprone, and deferasirox are also evaluated for inclusion of subsets of young children, especially those less than 6 years of age. Evidence on the efficacy and safety of iron chelation therapy for children ≥2 years of age with transfusional iron overload is widely available. New data exploring the risks and benefits of early‐start iron chelation in younger patients with minimal iron overload are also emerging.

Subjects

MeSH terms (MEDLINE)

beta-ThalassemiaIron Chelating AgentsIron OverloadChelation TherapyBlood TransfusionHumansChildChild, PreschoolDeferoxamineDeferipronePyridones

Author keywords

ferritinheartiron chelationiron overloadliverthalassemia

Substances

Iron Chelating AgentsDeferoxamineDeferipronePyridones

Authors and institutions

  • ForAnemia Foundation, Genoa, Italy.
  • First Department of Pediatrics, National and Kapodistrian University of Athens, Athens, Greece.
  • Division of Hematology, University of Toronto, Toronto, Ontario, Canada.
  • Campus of Haematology Franco and Piera Cutino, AOOR Villa Sofia-V. Cervello, Palermo, Italy.
  • Division of Hematology and Oncology, Department of Pediatrics, Weill Cornell Medicine, New York, New York, USA.
  • Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.

ORCID profiles: Gian Luca Forni, Kevin H M Kuo, Ali T Taher, Vip Viprakasit

Funding

  • Pharmacosmos

Cite

APA

Forni, G. L., Kattamis, A., Kuo, K. H. M., Maggio, A., Sheth, S., Taher, A. T., & Viprakasit, V. (2024). Iron chelation therapy for children with transfusion‐dependent β‐thalassemia: How young is too young?. Pediatric Blood & Cancer, 71(8). https://doi.org/10.1002/pbc.31035

Vancouver

Forni GL, Kattamis A, Kuo KHM, Maggio A, Sheth S, Taher AT, et al. Iron chelation therapy for children with transfusion‐dependent β‐thalassemia: How young is too young?. Pediatric Blood & Cancer. 2024;71(8). doi:10.1002/pbc.31035

BibTeX
@article{Forni2024,
  author = {Forni, Gian Luca and Kattamis, Antonis and Kuo, Kevin H M and Maggio, Aurelio and Sheth, Sujit and Taher, Ali T and Viprakasit, Vip},
  title = {Iron chelation therapy for children with transfusion‐dependent β‐thalassemia: How young is too young?},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  volume = {71},
  number = {8},
  doi = {10.1002/pbc.31035}
}
Start for free →